MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, reported that its life science business sector is investing €35 million in biosafety testing at its Glasgow and Stirling sites in Scotland. Biosafety testing is a critical step in the drug development and manufacturing process that ensures drugs are safe, efficacious, and meet regulatory requirements. The expansion will create nearly 500 new jobs, bringing the company’s workforce to over 1,200 employe...